SCHEDULE: Eventide Asset Management Discloses 6.3% Stake in Ovid Therapeutics

Eventide Asset Management, LLC, along with individuals Finny Kuruvilla and Robin C. John, have reported beneficial ownership of 11,812,241 shares, representing 6.3% of Ovid Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• Eventide Asset Management, LLC, through its investment in the Eventide Healthcare & Life Sciences Fund, beneficially owns 11,812,241 shares of Ovid Therapeutics Inc. common stock.
• This holding represents 6.3% of the company's outstanding common stock as of June 30, 2026.
• Finny Kuruvilla, M.D., Ph.D., and Robin C. John are also listed as reporting persons with shared voting and dispositive power over these shares.
• The filing is an amendment to a Schedule 13G, indicating a passive investment approach.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating significant institutional ownership and a stable, albeit not rapidly growing, stake in the company.

Positives

• Significant institutional ownership by Eventide Asset Management, LLC, demonstrating confidence in Ovid Therapeutics.
• A substantial stake of 6.3% indicates a notable investment by a specialized healthcare fund.
• The filing confirms a stable, long-term investment perspective rather than a short-term trading strategy.

Negatives

• The filing does not provide any new strategic information or operational updates, focusing solely on ownership disclosure.
• The passive nature of the investment (Schedule 13G) suggests no immediate plans for active influence or strategic direction changes by the reporting persons.

Risks

• Potential for future changes in Eventide's investment strategy, which could lead to a sale of shares and impact Ovid's stock price.
• The concentration of ownership among a few reporting persons could lead to coordinated selling if their investment thesis changes.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Ovid Therapeutics. It solely reports on the ownership stake of Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John.

Management Comments

• Each of the reporting persons expressly disclaims the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

Industry Context

StockSavvy.ai notes that significant institutional filings like this often reflect a belief in the underlying company's long-term potential within the biotechnology or pharmaceutical sector. The passive nature of the Schedule 13G filing suggests Eventide views Ovid Therapeutics as a strategic investment rather than an activist target.

Stakeholder Impact

• Shareholders: Increased confidence due to significant institutional backing, but potential for price volatility if this stake is reduced.
• Ovid Therapeutics Management: May benefit from a stable, supportive institutional investor, but lacks direct engagement on strategic decisions due to the passive filing.

Next Steps

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John will continue to hold their shares in Ovid Therapeutics Inc.
• Future amendments to this Schedule 13G will be filed if there are material changes in ownership or investment strategy.

Key Dates

Recommendation

The filing indicates a significant, stable institutional investment, which is a positive signal. However, as it's a passive ownership disclosure (Schedule 13G) and lacks new operational or financial data, it doesn't provide a strong catalyst for a buy or sell decision. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions while awaiting further company-specific developments.

Keywords

Ovid Therapeutics, Eventide Asset Management, Schedule 13G, Institutional Ownership, Beneficial Ownership, Healthcare Fund, Common Stock, Investment Adviser